Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Helsing und OHB gründen Joint Venture „Kirk“ für Bundeswehrauftrag „Spock“ (Börsen-Zeitung) +++ OHB Aktie +3,35%

ALDEYRA Aktie

 >ALDEYRA Aktienkurs 
1.355 EUR    (TradegateBSX)
Ask: 1.37 EUR / 2910 Stück
Bid: 1.34 EUR / 2950 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ALDEYRA Aktie über LYNX handeln
>ALDEYRA Performance
1 Woche: -2,1%
1 Monat: -7,2%
3 Monate: -66,7%
6 Monate: -66,5%
1 Jahr: -25,6%
laufendes Jahr: -67,9%
>ALDEYRA Aktie
Name:  ALDEYRA THERAPEUT.DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US01438T1060 / A111X8
Symbol/ Ticker:  137 (Frankfurt) / ALDX (NASDAQ)
Kürzel:  FRA:137, ETR:137, 137:GR, NASDAQ:ALDX
Index:  -
Webseite:  https://www.aldeyra.com/
Profil:  Aldeyra Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing therapies for immune-mediated and metabolic diseases. Its proprietary reactive aldehyde species (RASP) modulator platform underpins key product ..
>Volltext..
Marktkapitalisierung:  87.17 Mio. EUR
Unternehmenswert:  44.17 Mio. EUR
Umsatz:  -
EBITDA:  -24.19 Mio. EUR
Nettogewinn:  -23.54 Mio. EUR
Gewinn je Aktie:  -0.39 EUR
Schulden:  13.34 Mio. EUR
Liquide Mittel:  55.91 Mio. EUR
Operativer Cashflow:  -
Bargeldquote:  2.67
Umsatzwachstum:  -
Gewinnwachstum:  55.58%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  ALDEYRA
Letzte Datenerhebung:  19.05.26
>ALDEYRA Kennzahlen
Aktien/ Unternehmen:
Aktien: 60.32 Mio. St.
Frei handelbar: 96.82%
Rückkaufquote: -0.19%
Mitarbeiter: 8
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Buy
Kursziel: 316.65%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 2.36
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -34.28%
Eigenkaprendite: -51.76%
>ALDEYRA Peer Group
 
19.05.26 - 03:09
 ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX (PR Newswire)
 
NEW YORK, May 18, 2026 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29,......
15.05.26 - 03:57
 INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX (PR Newswire)
 
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or......
14.05.26 - 17:39
 ALDX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to......
11.05.26 - 01:03
 ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm (PR Newswire)
 
NEW YORK, May 10, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29,......
07.05.26 - 15:06
 ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Misrepresented Clinical Trial Results: SueWallSt (PR Newswire)
 
Important Notice Regarding Alleged Clinical Trial Efficacy Misrepresentations NEW YORK, May 7, 2026 /PRNewswire/ -- SueWallSt notifies investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) that a class action lawsuit has been filed on behalf of shareholders who purchased securities......
05.05.26 - 20:45
 ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm (PR Newswire)
 
NEW YORK, May 5, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026......
05.05.26 - 15:09
 ALDX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to......
01.05.26 - 01:45
 INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX (PR Newswire)
 
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or......
01.05.26 - 00:36
 ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm (PR Newswire)
 
NEW YORK, April 30, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29,......
30.04.26 - 15:36
 ALDX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to......
28.04.26 - 15:03
 ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline (PR Newswire)
 
NEW YORK, April 28, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). Shareholders who purchased shares of ALDX during the class period listed are encouraged to contact the firm regarding possible lead......
28.04.26 - 04:18
 ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm (PR Newswire)
 
NEW YORK, April 27, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29,......
21.04.26 - 15:51
 ALDX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to......
21.04.26 - 00:18
 ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm (PR Newswire)
 
NEW YORK, April 20, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29,......
20.04.26 - 08:30
 Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX (PR Newswire)
 
LOS ANGELES, April 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated......
17.04.26 - 14:21
 ALDX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to......
16.04.26 - 03:24
 Robbins LLP Encourages ADLX Stockholders Who Lost Money Investing in Aldeyra Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action (PR Newswire)
 
SAN DIEGO, April 15, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra......
15.04.26 - 21:06
 ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm (PR Newswire)
 
NEW YORK, April 15, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29,......
12.04.26 - 15:01
 ALDX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to......
10.04.26 - 23:03
 ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm (PR Newswire)
 
NEW YORK, April 10, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29,......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Veni, vidi, vici - Ich kam, ich sah, ich siegte. (Caesar über die Schlacht bei Zela gegen Pharnakos II., 47 v. Chr.). - Gajus Julius Caesar
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!